195 related articles for article (PubMed ID: 30873952)
1. Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies.
Verboom DM; van der Houwen TB; Kappen JH; van Daele PLA; Dik WA; Schreurs MWJ; van Hagen PM; van Laar JAM
Clin Exp Rheumatol; 2019; 37 Suppl 121(6):43-47. PubMed ID: 30873952
[TBL] [Abstract][Full Text] [Related]
2. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
[TBL] [Abstract][Full Text] [Related]
4. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.
Aikawa NE; Gonçalves C; Silva CA; Gonçalves C; Bonfá E; de Carvalho JF
Rheumatol Int; 2011 Aug; 31(8):1097-9. PubMed ID: 20012049
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
[No Abstract] [Full Text] [Related]
6. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
7. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
8. Long-term data on efficacy and safety of adalimumab in Behçet's disease.
van der Houwen TB; Humer B; Missotten TO; Thiadens AAHJ; van Hagen PM; van Laar JAM
Clin Immunol; 2023 Feb; 247():109242. PubMed ID: 36717068
[TBL] [Abstract][Full Text] [Related]
9. Chronic signs of memory B cell activation in patients with Behçet's disease are partially restored by anti-tumour necrosis factor treatment.
van der Houwen TB; van Hagen PM; Timmermans WM; Bartol SJ; Lam KH; Kappen JH; van Zelm MC; van Laar JA
Rheumatology (Oxford); 2017 Jan; 56(1):134-144. PubMed ID: 27744360
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
Desbois AC; Biard L; Addimanda O; Lambert M; Hachulla E; Launay D; Ackermann F; Pérard L; Hot A; Maurier F; Mausservey C; Bernard F; Noel N; Alric L; Mirault T; Cohen F; Boussouar S; Resche-Rigon M; Cacoub P; Saadoun D
Clin Immunol; 2018 Dec; 197():54-59. PubMed ID: 30125675
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.
Vitale A; Emmi G; Lopalco G; Gentileschi S; Silvestri E; Fabiani C; Urban ML; Frediani B; Galeazzi M; Iannone F; Rigante D; Cantarini L
Clin Rheumatol; 2017 Feb; 36(2):451-455. PubMed ID: 27679471
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
Interlandi E; Leccese P; Olivieri I; Latanza L
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature.
Aksoy A; Yazici A; Omma A; Cefle A; Onen F; Tasdemir U; Ergun T; Direskeneli H; Alibaz-Oner F
Int J Rheum Dis; 2020 Feb; 23(2):256-261. PubMed ID: 31976619
[TBL] [Abstract][Full Text] [Related]
14. Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; di Scala G; Guerriero S; Orlando I; Franceschini R; Capozzoli M; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2018 Jun; 37(6):1715-1720. PubMed ID: 29671190
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Adalimumab in Behçet Disease Patients on Clinical Manifestations and on Pro-Inflammatory Cytokines Milieu: Long-Term Follow-Up.
Braun-Moscovici Y; Tavor Y; Markovits D; Toledano K; Rozin A; Nahir MA; Balbir-Gurman A
Isr Med Assoc J; 2020 May; 22(5):289-293. PubMed ID: 32378820
[TBL] [Abstract][Full Text] [Related]
16. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
17. Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.
Chung SH; Park SJ; Hong SP; Cheon JH; Kim TI; Kim WH
World J Gastroenterol; 2013 Aug; 19(32):5389-92. PubMed ID: 23983446
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab in the treatment of pediatric Behçet's disease: case-based review.
Poddighe D; Mukusheva Z; Dauyey K; Assylbekova M
Rheumatol Int; 2019 Jun; 39(6):1107-1112. PubMed ID: 30976833
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.
Olivieri I; Leccese P; D'Angelo S; Padula A; Nigro A; Palazzi C; Coniglio G; Latanza L
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S54-7. PubMed ID: 21968237
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
